Agilent Technologies
A
$169.09
-0.14%
Agilent Technologies is a leading life sciences and diagnostics company that provides measurement technologies, instruments, consumables, and services across three operating segments: life sciences and diagnostics, Agilent CrossLab (consumables and services), and applied markets. Spun out of Hewlett-Packard in 1999, the company has evolved into a diversified platform serving biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, academic, and government end markets, with over half of sales derived from the sticky biopharma, chemical, and advanced materials verticals. The current investor narrative centers on Agilent's ability to sustain mid-single-digit revenue growth while expanding margins, aided by strategic M&A such as the Biocare Medical acquisition to bolster its pathology franchise. Recent quarterly results beat expectations and management raised full-year profit guidance, fueling positive sentiment, though China exposure and integration risks remain key debates.…
A
Agilent Technologies
$169.09
Related headlines
Investment Opinion: Should I buy A Today?
Based on the synthesis of analyst consensus, valuation, and growth prospects, Agilent warrants a Hold rating. The company's strong operational execution, including 8.06% YoY revenue growth and margin expansion, is offset by a premium valuation (forward PE 24.83x) and limited upside to the average analyst target of $175.20 (4.4%). The consensus Buy rating (mean 1.82) and robust cash flow generation ($1.436B TTM FCF) support the business quality, but the risk/reward is balanced at current levels.
Supporting evidence for the Hold includes: 1) Revenue growth of 8.06% YoY in Q3 2026, with sequential increases; 2) Gross margin expansion to 55.48% from 52.61% in Q1 2026; 3) Strong free cash flow of $1.436B TTM, funding dividends and buybacks; 4) Analyst average target of $175.20, implying modest upside; and 5) A conservative balance sheet with debt-to-equity of 0.50. However, the forward PE of 24.83x is a 25-35% premium to the sector average of 18-20x, and the PEG ratio of 9.44 suggests the growth premium is stretched.
The biggest risks that could invalidate the thesis are: 1) A slowdown in China revenue due to trade tensions; 2) Integration issues with the Biocare acquisition; and 3) Multiple compression if earnings growth fails to meet the implied 28% increase. The rating would upgrade to Buy if the forward PE compresses below 20x or if revenue growth accelerates above 10% with margin expansion. It would downgrade to Sell if revenue growth decelerates below 5% or if gross margin falls below 52%. Relative to its history and peers, the stock appears overvalued, trading near the upper end of its historical PE range and at a premium to the sector.
Sign up to view all
A 12-Month Price Forecast
Agilent presents a balanced risk/reward profile. The company's consistent execution, margin expansion, and strong cash flow are positives, but the premium valuation and limited upside to analyst targets suggest the stock is fairly valued. The base case (55% probability) targets $170-180, aligned with the average analyst target. The bull case (25%) could see $190-200 if growth accelerates, while the bear case (20%) could drop to $140-155 on China or integration issues. I would upgrade to bullish if revenue growth exceeds 10% with margin expansion, or downgrade to bearish if growth falls below 5% or margins contract. The key monitorable is the Biocare integration and China performance.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Agilent Technologies's 12-month outlook, with a consensus price target around $176.50 and implied upside of +4.4% versus the current price.
Average Target
$176.50
0 analysts
Implied Upside
+4.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$155 - $195
Analyst target range
Agilent is covered by 20 analysts, with a consensus recommendation of "Buy" (mean rating 1.82 on a scale where 1 is Strong Buy and 5 is Strong Sell). The average target price is $175.20, implying an upside of approximately 4.4% from the current price of $167.78. The consensus leans bullish, supported by recent reiterations of Buy/Overweight ratings from major firms like Wells Fargo, RBC Capital, JP Morgan, and Goldman Sachs, all maintaining positive views. The estimated EPS average for the fiscal year is $9.00, which aligns with the forward PE of 24.83x.
The target price range spans from a low of $155 to a high of $190. The high target of $190 assumes continued revenue acceleration, margin expansion, and successful integration of acquisitions like Biocare, potentially driving multiple expansion. The low target of $155 reflects concerns about China exposure, competitive pressures, or a broader market downturn that could compress multiples. The spread of $35 (about 22% of the average target) indicates moderate uncertainty. Institutional ratings show a cluster of reiterations in late August 2026, with no downgrades, suggesting stable analyst confidence. The tight clustering of ratings around Buy/Outperform signals strong conviction, but the modest upside to the average target suggests the stock is fairly valued near-term.
Bulls vs Bears: A Investment Factors
The bull case for Agilent rests on accelerating revenue growth (8.06% YoY in Q3 2026), margin expansion (gross margin up to 55.48%), strong cash flow ($1.436B TTM FCF), and a consensus Buy rating with a $175.20 average target. However, the bear case highlights a premium valuation (forward PE 24.83x vs. sector 18-20x), limited upside to targets (4.4%), and risks from China exposure and acquisition integration. Currently, the bull evidence is stronger due to consistent operational execution and positive momentum, but the most critical tension is whether the premium multiple can be sustained if growth decelerates or margins compress. The resolution of this tension—likely revealed in upcoming earnings and guidance—will determine the stock's trajectory.
Bullish
- Accelerating Revenue Growth: Q3 2026 revenue of $1.878B grew 8.06% YoY, up from 5.4% in Q3 2025, and marked the third consecutive sequential increase from $1.798B in Q1 to $1.835B in Q2. This acceleration, coupled with a raised full-year outlook, suggests momentum is building across all three segments.
- Margin Expansion and Operating Leverage: Gross margin expanded to 55.48% in Q3 2026 from 52.61% in Q1 2026, while operating margin reached 23.64%. Net income rose to $362M (19.28% net margin) from $305M in Q1, demonstrating effective cost management and pricing power.
- Strong Cash Flow and Balance Sheet: TTM free cash flow of $1.436B and Q3 FCF of $439M provide ample funding for growth initiatives, dividends ($72M), and buybacks ($78M). With debt-to-equity of 0.50 and current ratio of 1.96, the balance sheet is conservative and supports strategic M&A like the Biocare acquisition.
- Analyst Consensus and Target Upside: 20 analysts rate the stock a Buy (mean 1.82), with an average target of $175.20, implying 4.4% upside. High target of $190 suggests 13.2% potential, and recent reiterations from major firms (Wells Fargo, RBC, JP Morgan, Goldman Sachs) signal confidence.
Bearish
- Premium Valuation vs. Peers and History: Forward PE of 24.83x and trailing PE of 31.89x are above the healthcare diagnostics sector average of 18-20x and near the upper end of Agilent's historical 15-35x range. PEG ratio of 9.44 suggests the premium is not justified by expected growth.
- Limited Near-Term Upside to Targets: The average analyst target of $175.20 offers only 4.4% upside from the current price of $167.78, and the stock is trading at 94.8% of its 52-week range. This narrow margin suggests the market has already priced in much of the good news.
- China Exposure and Macro Risks: Agilent derives significant revenue from China, and ongoing US-China trade tensions or economic slowdowns could pressure sales. The recent US-Iran deal and hawkish Fed stance add macro uncertainty, with beta of 1.241 amplifying market volatility.
- Integration and Execution Risks: The Biocare Medical acquisition aims to bolster pathology, but integration challenges could disrupt operations or fail to deliver expected synergies. Any misstep could lead to earnings misses and multiple compression.
A Technical Analysis
Agilent is in a sustained uptrend, with the stock up 20.97% over the past year and 45.29% over six months, significantly outpacing the S&P 500's 15.01% and 17.35% respective gains. At a current price of $167.78, the stock is trading at approximately 94.8% of its 52-week range (low of $108.35, high of $177.05), indicating strong momentum but also proximity to overbought territory. This positioning suggests the market is pricing in continued operational execution, yet the narrow distance to the high leaves limited room for error.
Short-term momentum is robust, with a 1-month gain of 10.83% and a 3-month gain of 28.38%, both accelerating from the 1-year trend. The relative strength versus the S&P 500 is striking: 10.24% over 1 month and 25.04% over 3 months, highlighting persistent outperformance. However, the recent pullback from the 52-week high of $177.05 to $167.78 (a decline of about 5.2% from the peak) could signal a temporary consolidation; the stock remains well above its 52-week low, and no RSI data is available to confirm overbought conditions, but the sharp 1-month surge warrants caution for mean reversion.
Key technical support lies near the 52-week low of $108.35, with intermediate support likely around the $150–155 area (previous resistance turned support). Resistance is at the 52-week high of $177.05; a breakout above this level would confirm the uptrend and could target new highs, while a breakdown below $150 would signal a deeper correction. The stock's beta of 1.241 indicates it is about 24% more volatile than the broader market, which amplifies both upside and downside moves and necessitates careful position sizing. The maximum drawdown of -29.87% over the past year further underscores the importance of risk management.
Beta
1.21
1.21x market volatility
Max Drawdown
-29.9%
Largest decline past year
52-Week Range
$108-$177
Price range past year
Annual Return
+22.0%
Cumulative gain past year
| Period | A Return | S&P 500 |
|---|---|---|
| 1m | +12.1% | +0.9% |
| 3m | +26.6% | +3.4% |
| 6m | +47.0% | +14.4% |
| 1y | +22.0% | +16.2% |
| ytd | +22.6% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
A Fundamental Analysis
Agilent's revenue trajectory is solidly growing, with the most recent quarter (Q3 2026, ended July 31, 2026) reporting $1.878 billion, up 8.06% year-over-year. Sequentially, revenue has increased from $1.798 billion in Q1 2026 to $1.835 billion in Q2 2026 to $1.878 billion in Q3 2026, demonstrating consistent top-line expansion. The Agilent CrossLab segment contributed $786 million, while Life Sciences and Applied Markets added $746 million and Applied Markets $346 million, indicating broad-based strength. This steady growth, coupled with a raised full-year outlook, supports a positive investment case, though the pace remains mid-single-digit, typical for a mature life sciences tools company.
Profitability is robust, with Q3 2026 net income of $362 million and a gross margin of 55.48%, up from 52.61% in Q1 2026 and 54.99% in Q2 2026. The net margin for the quarter was 19.28%, and operating margin stood at 23.64%, reflecting effective cost management and operating leverage. Compared to the industry, these margins are healthy for a diversified life sciences player, and the sequential gross margin improvement suggests pricing power and favorable product mix. The company's ability to expand margins while investing in R&D ($123 million in Q3) and pursuing acquisitions is a key strength.
The balance sheet is conservative, with a debt-to-equity ratio of 0.4976 and a current ratio of 1.957, indicating ample liquidity. Free cash flow for the trailing twelve months was $1.436 billion, and Q3 2026 free cash flow was $439 million, providing ample internal funding for growth initiatives, dividends ($72 million paid in Q3), and share repurchases ($78 million in Q3). The return on equity (ROE) of 19.33% and return on assets (ROA) of 8.63% demonstrate efficient capital utilization. With cash of $1.76 billion at the end of Q3, Agilent has the financial flexibility to pursue strategic M&A, such as the Biocare acquisition, without straining its balance sheet.
Quarterly Revenue
$1.9B
2026-07
Revenue YoY Growth
+8.1%
YoY Comparison
Gross Margin
55.5%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is A Overvalued?
Since Agilent is profitable with positive net income, the PE ratio is the primary valuation metric. The trailing PE is 31.89x, while the forward PE is 24.83x, implying the market expects significant earnings growth (approximately 28% increase) over the next year. This gap suggests that investors are pricing in a recovery in earnings, potentially driven by margin expansion and the full realization of recent acquisitions. The PEG ratio of 9.44, however, indicates that the current PE is high relative to expected growth, which could be a concern if growth does not materialize.
Compared to the industry average, Agilent's valuation appears rich. The healthcare sector (medical diagnostics & research) typically trades at a forward PE of around 18-20x, whereas Agilent's forward PE of 24.83x represents a premium of roughly 25-35%. The price-to-sales ratio of 5.96 and EV/EBITDA of 23.43 are also elevated, suggesting the market is awarding a premium for Agilent's strong market position, consistent cash flows, and growth prospects. However, the premium may be justified by Agilent's higher margins (gross margin 52.4%, operating margin 21.3%) and diversified revenue base compared to peers.
Historically, Agilent's PE ratio has ranged from around 15x to 35x over the past few years. The current trailing PE of 31.89x is near the upper end of this range, while the forward PE of 24.83x is more moderate. The price-to-book ratio of 6.14 is also above the historical average of around 5-6x, indicating that the stock is trading at a premium to its own history. This suggests that the market is pricing in optimistic expectations, and any disappointment in earnings or growth could lead to multiple compression.
PE
31.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for Agilent are moderate but noteworthy. The company carries a debt-to-equity ratio of 0.50 and a current ratio of 1.96, indicating a healthy balance sheet, but interest expense of $29M in Q3 2026 consumes a portion of operating income. While free cash flow is robust at $1.436B TTM, the company's growth relies on continued margin expansion; any reversal in gross margin (currently 55.48%) or operating margin (23.64%) could pressure earnings. Additionally, the Biocare acquisition introduces integration risk, and a significant portion of revenue is concentrated in biopharma and chemical end markets, making it vulnerable to sector-specific downturns.
Market and competitive risks are pronounced given Agilent's premium valuation. The forward PE of 24.83x and EV/EBITDA of 23.43 are above industry averages, leaving the stock susceptible to multiple compression if growth disappoints. The beta of 1.241 means the stock is 24% more volatile than the market, amplifying downside during selloffs. Competitive pressures in life sciences tools are intense, with rivals like Thermo Fisher and Danaher vying for market share. Regulatory headwinds, particularly around China trade policies and healthcare pricing, could also impact results. Recent news highlights a hawkish Fed and sticky inflation, which could pressure high-multiple stocks.
The worst-case scenario involves a combination of slowing revenue growth, margin contraction, and multiple compression. If China sales decline due to trade tensions and the Biocare integration falters, earnings could miss estimates, leading to a de-rating. The 52-week low of $108.35 represents a 35.4% downside from the current price of $167.78, and the analyst low target of $155 implies a 7.6% decline. A more severe scenario, such as a recession or competitive disruption, could push the stock toward the 52-week low, resulting in a loss of over 35% from current levels. Investors should be prepared for significant drawdowns, as evidenced by the max drawdown of -29.87% over the past year.
FAQ
The key risks for Agilent include: 1) Financial risks: The company's premium valuation (forward PE 24.83x) leaves it vulnerable to multiple compression if growth slows; debt-to-equity of 0.50 is manageable but interest expense of $29M in Q3 2026 consumes cash. 2) Competitive risks: Intense competition in life sciences tools from Thermo Fisher and Danaher could pressure pricing and market share. 3) Macro risks: China exposure and trade tensions could disrupt revenue, and the stock's beta of 1.241 makes it more volatile than the market. 4) Company-specific risks: Integration of Biocare Medical may not deliver expected synergies, and any earnings miss could trigger a sharp selloff. The most severe risk is a combination of China slowdown and integration failure, which could push the stock toward its 52-week low of $108.35, a 35% decline from current levels.
Our 12-month forecast for Agilent includes three scenarios: Bull case (25% probability) targets $190-200, driven by accelerated growth, successful Biocare integration, and multiple expansion. Base case (55% probability) targets $170-180, assuming mid-single-digit revenue growth, stable margins, and the stock trading near the analyst average target of $175.20. Bear case (20% probability) targets $140-155, reflecting a China slowdown, integration missteps, and margin contraction. The most likely scenario is the base case, with a key assumption that revenue grows 6-8% YoY and gross margins hold around 55%. The analyst consensus average target of $175.20 aligns with our base case, implying a 4.4% upside from the current price of $167.78.
Agilent appears overvalued relative to both its peers and its own history. The trailing PE of 31.89x and forward PE of 24.83x are above the healthcare diagnostics sector average of 18-20x, representing a 25-35% premium. The PEG ratio of 9.44 is particularly high, indicating that the market is paying a steep price for expected growth. Compared to its historical PE range of 15-35x, the current multiple is near the upper end. The price-to-sales ratio of 5.96 and EV/EBITDA of 23.43 are also elevated. This valuation implies the market expects significant earnings growth (approximately 28% increase) and successful execution of strategic initiatives. If growth disappoints, multiple compression could lead to a significant price decline.
Agilent is a good buy for long-term investors seeking exposure to the life sciences sector with a balanced risk/reward profile. The stock has strong fundamentals, including 8.06% YoY revenue growth, expanding margins (gross margin 55.48%), and robust free cash flow of $1.436B TTM. However, the forward PE of 24.83x is a premium to the sector, and the average analyst target of $175.20 implies only 4.4% upside, suggesting limited near-term appreciation. The biggest downside risk is a China slowdown or integration issues with Biocare, which could push the stock toward the 52-week low of $108.35. For investors with a long-term horizon and tolerance for volatility (beta 1.241), Agilent offers a quality business with steady growth, but those seeking high growth or deep value may find better opportunities elsewhere.
Agilent is more suitable for long-term investment rather than short-term trading. The company operates in a stable, growing industry with a diversified revenue base and consistent cash flow, making it a core holding for patient investors. However, the stock's beta of 1.241 and max drawdown of -29.87% over the past year indicate significant volatility, which could be challenging for short-term traders. The dividend yield is low at 0.68%, so income is not a primary attraction. Earnings visibility is moderate, with analyst estimates for EPS of $9.00 in the current fiscal year. A minimum holding period of 2-3 years is recommended to ride out market cycles and benefit from long-term growth and potential multiple expansion. Short-term traders might find opportunities around earnings announcements, but the risk/reward is less favorable given the premium valuation.